Group 1: Industry Insights - The recent national centralized procurement involves 316 commonly used drugs, with a procurement period extending to the end of 2028, providing stable expectations for the pharmaceutical industry, which may impact the order environment for Jiuzhou Pharmaceutical as a raw material and CDMO enterprise [1] - The innovative drug sector shows a clear recovery trend, with a 13.34% year-on-year increase in IND applications in 2025, leading to heightened demand in the CRO/CDMO industry, where leading companies like Jiuzhou Pharmaceutical are expected to benefit from optimized order structures [1] Group 2: Company Developments - Jiuzhou Pharmaceutical expressed significant potential in its peptide CDMO business, particularly after the patent expiration of Semaglutide, indicating the company will actively seize market opportunities, although specific impacts were not quantified [1] - The stock price of Jiuzhou Pharmaceutical has shown fluctuations, with a range of 0.89% over the past week and a trading volume of 1.05 billion yuan on February 12, 2026, closing at 18.08 yuan, reflecting a daily increase of 0.61% [2] - On February 12, 2026, there was a net inflow of 707.68 million yuan in main funds, reversing the previous day's net outflow of 1,751.05 million yuan, indicating a shift in investor sentiment [2]

Core Viewpoint - Tiger Med (300347) forecasts a net profit attributable to shareholders for 2025 to be between 830 million and 1.23 billion yuan, representing a year-on-year growth of 105% to 204% [1] Group 1: Financial Performance - The company expects significant improvement in investment income and fair value changes from non-current financial assets, which include investments in non-listed companies, listed company shares, and pharmaceutical funds [1] - The anticipated net new orders for 2025 are projected to be between 9.5 billion and 10.5 billion yuan, compared to 8.42 billion yuan in the same period of 2024 [1] Group 2: Industry Context - The recovery of China's innovative pharmaceutical industry is expected to lead to a noticeable increase in the value of innovative assets within the sector [1]

Core Viewpoint - The company, Tigermed (300347.SZ), expects a significant increase in net profit attributable to shareholders for 2025, projecting between 830 million to 1.23 billion RMB, representing a growth of 105% to 204% compared to the previous year [1] Financial Performance - The increase in profit is primarily due to a substantial rise in non-recurring gains and losses during the reporting period [1] - The company has seen a notable improvement in the disposal and holding gains of its non-current financial assets, which include equity stakes in non-listed companies, shares in listed companies, and pharmaceutical funds [1] Industry Context - The recovery of the Chinese innovative drug industry has contributed to the restoration of asset values [1] - The company has achieved good growth in both the number and value of new orders compared to the same period last year [1] Order Growth - For 2025, the company anticipates net new orders (newly signed orders minus canceled orders) to be in the range of 9.5 billion to 10.5 billion RMB, compared to 8.42 billion RMB in net new orders for the same period in 2024 [1]

Market Overview - The Hong Kong stock market experienced a decline, ending a three-day winning streak since 2026, with all three major indices closing lower [2][4] - The Hang Seng Index fell by 0.94%, the Hang Seng China Enterprises Index decreased by 1.14%, and the Hang Seng Technology Index dropped by 1.49% [4][6] - Southbound funds recorded a net inflow of 9.2 billion HKD [4] Sector Performance - Technology and automotive stocks underperformed, contributing to the decline of the Hang Seng Technology Index [5][7] - Financial stocks showed weakness, with Chinese brokerage stocks turning negative [5][11] - Conversely, the innovative pharmaceutical sector, along with certain materials and coal stocks, saw gains despite the overall market downturn [5][14] Technology Sector - Major technology stocks such as Tencent Music, Alibaba, and Netease saw significant declines, with Tencent Music dropping over 5% and Alibaba falling more than 3% [8][10] - The recent regulatory changes in the live-streaming e-commerce sector are aimed at enhancing industry supervision and protecting consumer rights, which may impact market dynamics [8] Automotive Sector - Multiple research institutions predict a potential 7% decline in China's automotive market sales for 2026, marking the first annual negative growth since 2020 [9] Financial Sector - The financial sector faced a downturn, particularly among brokerage stocks, with notable declines including over 6% for China Merchants International and over 5% for Guotai Junan [12][13] Pharmaceutical Sector - The innovative pharmaceutical sector showed resilience, with stocks like Rongchang Bio rising by 12.93% and other companies like Kangfang Bio and WuXi Biologics also performing well [14][15] - A report from Zhongtai Securities indicates positive changes in the CRO and CDMO industries, driven by improving investment environments and supportive policies [16] Materials and Coal Sector - The materials sector, particularly aluminum and coal stocks, performed well, with Nanshan Aluminum rising over 10% [18][19] - Research from GF Securities suggests that the coal industry is experiencing structural demand optimization, with a projected 5% growth in coal demand from the chemical sector [19][20]